TITLE

Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study

AUTHOR(S)
Dunn, David
PUB. DATE
December 2005
SOURCE
BMJ: British Medical Journal (International Edition);12/10/2005, Vol. 331 Issue 7529, p1368
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective To examine whether the level of primary resistance to HIV drugs is increasing in the United Kingdom. Design Multicentre observational study. Setting All virology laboratories in the United Kingdom carrying out tests for HIV resistance as part of routine clinical care. Participants 2357 people infected with HIV who were tested for resistance before receiving antiretroviral therapy. Main outcome measure Prevalence of drug resistance on basis of the Stanford genotypic interpretation system. Results Over the study period (February 1996 to May 2003), 335 (14.2%, 95% confidence interval 12.8% to 15.7%) samples had mutations that conferred resistance to one or more antiretroviral drugs (9.3% high level resistance, 5.9% medium level resistance). The prevalence of primary resistance has increased markedly over time, although patterns are specific to drug class; the largest increase was for non-nucleoside reverse transcriptase inhibitors. In 2002-3, the prevalence of resistance to any antiretroviral drug to nucleoside or nucleotide reverse transcriptase inhibitors, to non-nucleoside reverse transcriptase inhibitors, or to protease inhibitors was 19.2% (15.7% to 23.2%), 12.4% (9.5% to 15.9%), 8.1% (5.8% to 11.1%), and 6.6% (4.4% to 9.3%), respectively. The risk of primary resistance was only weakly related to most demographic and clinical factors, including ethnicity and viral subtype. Conclusions The United Kingdom has one of the highest reported rates of primary resistance to HIV drugs worldwide. Prevalence seems still to be increasing and is high in all demographic subgroups.
ACCESSION #
19148732

 

Related Articles

  • Relationship between HIV/Highly Active Antiretroviral Therapy (HAART)—Associated Lipodystrophy Syndrome and Stavudine-Triphosphate Intracellular Levels in Patients with Stavudine-Based Antiretroviral Regimens. Domingo, Pere; Cabeza, Maria Carmen; Pruvost, Alain; Salazar, Juliana; del Mar Gutierrez, Maria; Mateo, Maria Gracia; Domingo, Joan C.; Fernandez, Irene; Villarroya, Francesc; Muñoz, Jessica; Vidal, Francesc; Baiget, Montserrat // Clinical Infectious Diseases;4/1/2010, Vol. 50 Issue 7, p1033 

    Background. The link between human immunodeficiency virus/highly active antiretroviral therapy (HAART)- associated lipodystrophy syndrome (HALS) and the use of thymidine analogues has been well established. However, to our knowledge, no relationship has been proven between intracellular levels...

  • Sequential vs. simultaneous antiretroviral HIV therapy. Huffman, Grace Brooke // American Family Physician;11/15/1998, Vol. 58 Issue 8, p1845 

    Focuses on how antiretroviral therapy that consists of a combination of two nucleoside analog reverse transcriptase inhibitors can suppress viral load in patients with human immunodefiency virus (HIV) infection. Methods used in the study; Results and discussion; Conclusion.

  • How HIV Treatment Failure Occurs Without Resistance. Breindl, Anette // BioWorld Today;9/5/2012, Vol. 23 Issue 172, p1 

    The article reports on a mathematical model developed by scientists which may be able to help determine the best way to prevent resistance to currently available HIV drugs and identify effective combinations of new drugs early on in clinical development. According to Alison Hill of Harvard...

  • Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. Hogg, Robert S.; Yip, Benita; Kully, Charlotte; Craib, Kevin J.P.; O'Shaughnessy, Michael V.; Schechter, Martin T.; Montaner, Julio S.G. // CMAJ: Canadian Medical Association Journal;3/09/99, Vol. 160 Issue 5, p659 

    Compares mortality and AIDS-free survival among HIV-infected patients in British Columbia who were treated with double- and triple-drug regimes. Methods; Results; Interpretation that treatment with a triple-drug antiretroviral regimen comprising 2 nucleoside analogue reverse transcriptase...

  • Undiagnosed Active Tuberculosis in HIV-Infected Patients Commencing Antiretroviral Therapy. Meintjes, Graeme; Wilkinson, Robert J. // Clinical Infectious Diseases;10/1/2010, Vol. 51 Issue 7, p830 

    The authors offer insights regarding complications of antiretroviral therapy (ART) in patients infected with human immunodeficiency virus (HIV) in sub-Saharan, Africa. They stress that undiagnosed active tuberculosis is the significant clinical complication among patients who received ART care....

  • Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients. Kapoor, Amit; Shapiro, Beth; Shafer, Robert W.; Shulman, Nancy; Soo-Yon Rhee; Delwart, Eric L. // Retrovirology;2008, Vol. 5, Special section p1 

    Background: Combination anti-viral therapies have reduced treatment failure rates by requiring multiple specific mutations to be selected on the same viral genome to impart high-level drug resistance. To determine if the common protease inhibitor resistance mutation L90M is only selected once or...

  • Virtual Screening for Potential Substances for the Prophylaxis of HIV Infection in Libraries of Commercially Available Organic Compounds. Lagunin, A. A.; Filimonov, D. A.; Gloriozova, T. A.; Tarasova, O. A.; Zakharov, A. V.; Guasch, L.; Nicklaus, M. C.; Poroikov, V. V. // Pharmaceutical Chemistry Journal;Oct2013, Vol. 47 Issue 7, p343 

    The search for new substances for the treatment and prophylaxis of HIV-AIDS remains relevant despite advances in highly active antiretroviral therapy (HAART), both because of the appearance of resistance to existing agents and because of their side effects and toxicity. Preventing the spread of...

  • Antiretroviral Therapy: Optimal Sequencing of Therapy to Avoid Resistance. Martinez-Cajas, Jorge L.; Wainberg, Mark A. // Drugs;2008, Vol. 68 Issue 1, p43 

    In the second decade of highly active antiretroviral therapy, drug regimens offer more potent, less toxic and more durable choices. However, strategies addressing convenient sequential use of active antiretroviral combinations are rarely presented in the literature. Studies have seldom directly...

  • HIV clinical trials are not enough. Millson, Margaret E.; Rachlis, Anita R. // CMAJ: Canadian Medical Association Journal;3/09/99, Vol. 160 Issue 5, p669 

    Editorial. Discusses antiretroviral drug regimens for HIV infection. The paradigm of HIV therapy being complete suppression of viral replication to preserve and restore immune function and to delay or prevent the emergence of drug resistance; Reference to a study by Robert S. Hogg and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics